[Perspectives on the pharmacotherapy of diseases extending with advanced oxidation protein products participation].
In the view of constantly increasing number of reports about participation of advanced oxidation protein products (AOPPs) in pathogenesis of many diseases as well as in the pathomechanism of their biochemical disturbances and clinical complications, the possibility of treatment of these diseases by reducing of AOPPs concentration and prevention or inhibition of their formation poses the object of intensive investigations. The first investigated agents, with proven efficacy in prevention of AOPPs formation, was N-acetylcysteine. In relationship with the fact, that the intensified formation of AOPPs is closely connected with intensity of oxidative stress (OS), so the possibility of use of agents and/or drugs with well-known antioxidative proprieties, also natural origin, was examined. It is very important in aspects of its self-treatment by patients. The next step was the estimation of possibility of utilization of pleiotropic properties of drugs routinely applied in the treatment of civilization diseases, especially hypertension and diabetes, often with kidneys insufficiency. On the basis of known mechanism of the unfavorable acting of AOPPs (induction of intracellular signal transduction, and secondary intensyfication of OS), on the way of its connection with the RAGE receptor [similarly as advanced glycation end products (AGEs)], indicated on the possibility of new therapeutic strategies, through the blocking of RAGE-AGEs interactions or using the soluble form of this receptor. Discussed in this paper results of investigations shows the possibility to introduction in the near future, the innovative therapeutic strategies, directed just on the AOPPs, permitting on the limitation of their formation and accumulation in tissues and organs, especially in kidneys. This will permit for the break of mechanism of vicious circle of interaction OS and oxidatively modified macromolecules and attenuating of biochemical and clinical disturbances in the diseases connected with AOPPs participating.
Katedra i Zakład Toksykologii, Wydział Farmaceutyczny z Oddziałem Analityki Medycznej, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu.
Agnieszka
A
Piwowar
D062107:Advanced Oxidation Protein Products / Q000378:metabolism* / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000378:metabolism* / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism
D062107:Advanced Oxidation Protein Products; D000975:Antioxidants; D017127:Glycation End Products, Advanced